Feeding the soil AND feeding the cow – Conservation Agriculture in Kenya

One of the main obstacles to the implementation of Conservation Agriculture (CA) in subSaharan Africa is the priority given to using crop residues as cattle feed rather than mulching material. As documented in past projects (e.g. CA-SARD, CA2Africa, ABACO), in this way the CA approach will not reach its full potential - particularly in countries with a limited biomass production due to climatic conditions. To identify pathways for enabling an implementation of CA that is not in conflict with other goals of farmers’ livelihoods (e.g. livestock farming), we used a transformative learning approach with farmers and other stakeholders in Laikipia County (Kenya). The learning elements comprised: a timeline that encompasses the past promotion activities; stakeholder mapping which highlights the various stakeholders involved and their influence; non-scripted participatory videos filmed by the stakeholders themselves that show the farming system from different perspectives; focus group discussions structured by the Qualitative expert Assessment Tool for CA adoption in Africa (QAToCA). Challenges to CA adoption that were jointly identified include the competition for fodder, a lack of financial resources to get started with CA. There are knowledge gaps on proper application of CA equipment, on the fodder production and conservation options and, lastly, on sustainable crop-livestock production systems. Furthermore, farmers feel disconnected from existing governmental support. However, our findings highlight solutions which enable feeding the soil “and” feeding the cow. Some farmers already have started to grow forages on their farms in order to reduce dependence on crop residues as a feeding source – an approach which had not been promoted during past projects. This shows the importance of an enabling environment provided by government programs which supports long-term extension efforts combined with farmers’ willingness to jointly learn towards a more sustainable agriculture. On farms where both systems (CA and conventional) are practised, women play an important role by experimenting with CA practices, thereby realising promising results in terms of yield and drought resilience. Furthermore, our findings underline the need for a long-term monitoring of innovation processes which is often not possible within short-term term research projects and promotion programs

Innovative Conservation Agriculture Approaches: Food Security and Climate Action through Soil and Water Conservation (INCAA)

The crucial challenge for smallholder farmers in sub-Saharan Africa is feeding a growing population while preserving the natural resource base of the agricultural system. In future, this challenge will be exacerbated by soil degradation and climate change. Conservation Agriculture (CA) has been promoted as a strategy that can improve yields, soils and effective water use. CA thus has potential to increase the resilience of farming systems facing the mentioned challenges. However, CA since its introduction in sub-Sahara Africa has not moved from the invention to the innovation stage: the CA innovation seen as a package is not meeting the farmers’ needs, capabilities and opportunities. Overall, the attempt to transfer this innovation in a conventional linear way from science to farm has been disappointing. The INCAA project is designed as an action research process aimed at targeting the challenging (and often missing) interfaces of science-driven technology and local realities in innovation systems. The overall objective of INCAA is to mentor and analyse a learning process that supports the innovation of CA in sub-Saharan Africa. The case studies of the project are Laikipia County, Kenya and Koumbia District, Burkina Faso. Building on the experiences of past projects, INCAA will (1) map benefits and adaptations of CA in innovation systems around the partner projects; (2) foster joined learning of stakeholders to test and validate CA tools; and (3) develop learning strategies for an innovation process towards CA including institutional and individual dimensions. This project will start from those who take the final decision on the fate of CA - the farmers. By assessing how farmers have actually adapted and implemented CA, we can derive lessons on the benefits and losses related to such CA modes for all stakeholders involved in the agricultural system. This contribution will 1) introduce the overall conceptual, methodological and structural design of the project and 2) highlight its first preliminary results which so far show high influence of gender aspects towards the adoption decision process. Differing roles of and expectations towards men and women within the farming communities are often an invisible obstacle for further adoption of CA

ISOLAMENTO DO Ureaplasma diversum EM MUCO VULVOVAGINAL DE VACAS LEITEIRAS REPETIDORAS DE ESTRO NO ESTADO DE ALAGOAS BRASIL

Ureaplasma diversum is an opportunistic bacteria of the bovine genital tract and an important agent in granular vulvovaginitis, abortion, low fertility herd rate and respiratory problems in calves. The aim of this work was to study the relationship between positive cultures for Ureaplasma diversum and the extension and severity of the lesions in the vaginal mucosa of repeat breeders dairy cows in Alagoas State, Brazil. Visual evaluation were performed in 93 cows to evaluate the vaginal lesion score (VLS), classified according the lesion severity and extension (0 to 4, with 0= no lesions, 4= severe inflammation and local necrosis). The VLS 1 was the most frequent (51,61%). VLS 0 was present in 17,2% of the females, while 29,03% and 2,16% showed VLS 2 and 3, respectively. None of the cows showed VLS 4. Vaginal swab samples were obtained from 24 females (25%). Of them, 41,7% were positive for U. diversum. The presence of U. diversum was associated positively to VLS, especially to those cows showing vaginal lesion score 1. The present results indicated that Ureaplasma diversum should be considered responsible for low reproductive efficiency, carrying out to repeat breeding, probably because of embryo mortality.O Ureaplasma diversum é um patógeno oportunista do trato genital dos bovinos que causa surtos de vulvovaginite granular, seguidos de abortamento e redução da eficiência reprodutiva do rebanho. O presente estudo foi desenvolvido com o objetivo de avaliar a relação entre a extensão e a gravidade das lesões de vulvovaginite observadas com o isolamento de Ureaplasma diversum em amostras colhidas diretamente da mucosa vulvovaginal, em fêmeas de aptidão leiteira repetidoras de estro no estado de Alagoas, Brasil. A avaliação da extensão e severidade das lesões foi feita em 93 vacas com histórico de repetição regular de estro após três ou mais inseminações artificiais, seguindo-se a seguinte metodologia de classificação: graus de 0 a 4, sendo 0=sem lesões; 4=lesões severas, com hemorragia e necrose. Dos 93 animais avaliados, 17,2% apresentavam lesão grau 0; 51,61% grau 1; 29,03% grau 2; 2,16% grau 3 e nenhum animal mostrou lesão de grau 4. Foi colhido muco vulvovaginal de 24 vacas, escolhidas aleatoriamente, para processamento bacteriológico, encontrando-se 41,67% das amostras positivas para Ureaplasma diversum. O isolamento do agente esteve positivamente relacionado à presença de lesões na mucosa vulvovaginal, especialmente àquelas de grau 1. Os resultados deste estudo indicam que o Ureaplasma diversum deve ser considerado como agente responsável por queda na eficiência reprodutiva, promovendo retorno ao estro, provavelmente em conseqüência de mortalidade embrionária

Primary stroke prevention worldwide : translating evidence into action

Funding Information: The stroke services survey reported in this publication was partly supported by World Stroke Organization and Auckland University of Technology. VLF was partly supported by the grants received from the Health Research Council of New Zealand. MOO was supported by the US National Institutes of Health (SIREN U54 HG007479) under the H3Africa initiative and SIBS Genomics (R01NS107900, R01NS107900-02S1, R01NS115944-01, 3U24HG009780-03S5, and 1R01NS114045-01), Sub-Saharan Africa Conference on Stroke Conference (1R13NS115395-01A1), and Training Africans to Lead and Execute Neurological Trials & Studies (D43TW012030). AGT was supported by the Australian National Health and Medical Research Council. SLG was supported by a National Heart Foundation of Australia Future Leader Fellowship and an Australian National Health and Medical Research Council synergy grant. We thank Anita Arsovska (University Clinic of Neurology, Skopje, North Macedonia), Manoj Bohara (HAMS Hospital, Kathmandu, Nepal), Denis ?erimagi? (Poliklinika Glavi?, Dubrovnik, Croatia), Manuel Correia (Hospital de Santo Ant?nio, Porto, Portugal), Daissy Liliana Mora Cuervo (Hospital Moinhos de Vento, Porto Alegre, Brazil), Anna Cz?onkowska (Institute of Psychiatry and Neurology, Warsaw, Poland), Gloria Ekeng (Stroke Care International, Dartford, UK), Jo?o Sargento-Freitas (Centro Hospitalar e Universit?rio de Coimbra, Coimbra, Portugal), Yuriy Flomin (MC Universal Clinic Oberig, Kyiv, Ukraine), Mehari Gebreyohanns (UT Southwestern Medical Centre, Dallas, TX, USA), Ivete Pillo Gon?alves (Hospital S?o Jos? do Avai, Itaperuna, Brazil), Claiborne Johnston (Dell Medical School, University of Texas, Austin, TX, USA), Kristaps Jurj?ns (P Stradins Clinical University Hospital, Riga, Latvia), Rizwan Kalani (University of Washington, Seattle, WA, USA), Grzegorz Kozera (Medical University of Gda?sk, Gda?sk, Poland), Kursad Kutluk (Dokuz Eylul University, ?zmir, Turkey), Branko Malojcic (University Hospital Centre Zagreb, Zagreb, Croatia), Micha? Maluchnik (Ministry of Health, Warsaw, Poland), Evija Migl?ne (P Stradins Clinical University Hospital, Riga, Latvia), Cassandra Ocampo (University of Botswana, Princess Marina Hospital, Botswana), Louise Shaw (Royal United Hospitals Bath NHS Foundation Trust, Bath, UK), Lekhjung Thapa (Upendra Devkota Memorial-National Institute of Neurological and Allied Sciences, Kathmandu, Nepal), Bogdan Wojtyniak (National Institute of Public Health, Warsaw, Poland), Jie Yang (First Affiliated Hospital of Chengdu Medical College, Chengdu, China), and Tomasz Zdrojewski (Medical University of Gda?sk, Gda?sk, Poland) for their comments on early draft of the manuscript. The views expressed in this article are solely the responsibility of the authors and they do not necessarily reflect the views, decisions, or policies of the institution with which they are affiliated. We thank WSO for funding. The funder had no role in the design, data collection, analysis and interpretation of the study results, writing of the report, or the decision to submit the study results for publication. Funding Information: The stroke services survey reported in this publication was partly supported by World Stroke Organization and Auckland University of Technology. VLF was partly supported by the grants received from the Health Research Council of New Zealand. MOO was supported by the US National Institutes of Health (SIREN U54 HG007479) under the H3Africa initiative and SIBS Genomics (R01NS107900, R01NS107900-02S1, R01NS115944-01, 3U24HG009780-03S5, and 1R01NS114045-01), Sub-Saharan Africa Conference on Stroke Conference (1R13NS115395-01A1), and Training Africans to Lead and Execute Neurological Trials & Studies (D43TW012030). AGT was supported by the Australian National Health and Medical Research Council. SLG was supported by a National Heart Foundation of Australia Future Leader Fellowship and an Australian National Health and Medical Research Council synergy grant. We thank Anita Arsovska (University Clinic of Neurology, Skopje, North Macedonia), Manoj Bohara (HAMS Hospital, Kathmandu, Nepal), Denis Čerimagić (Poliklinika Glavić, Dubrovnik, Croatia), Manuel Correia (Hospital de Santo António, Porto, Portugal), Daissy Liliana Mora Cuervo (Hospital Moinhos de Vento, Porto Alegre, Brazil), Anna Członkowska (Institute of Psychiatry and Neurology, Warsaw, Poland), Gloria Ekeng (Stroke Care International, Dartford, UK), João Sargento-Freitas (Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal), Yuriy Flomin (MC Universal Clinic Oberig, Kyiv, Ukraine), Mehari Gebreyohanns (UT Southwestern Medical Centre, Dallas, TX, USA), Ivete Pillo Gonçalves (Hospital São José do Avai, Itaperuna, Brazil), Claiborne Johnston (Dell Medical School, University of Texas, Austin, TX, USA), Kristaps Jurjāns (P Stradins Clinical University Hospital, Riga, Latvia), Rizwan Kalani (University of Washington, Seattle, WA, USA), Grzegorz Kozera (Medical University of Gdańsk, Gdańsk, Poland), Kursad Kutluk (Dokuz Eylul University, İzmir, Turkey), Branko Malojcic (University Hospital Centre Zagreb, Zagreb, Croatia), Michał Maluchnik (Ministry of Health, Warsaw, Poland), Evija Miglāne (P Stradins Clinical University Hospital, Riga, Latvia), Cassandra Ocampo (University of Botswana, Princess Marina Hospital, Botswana), Louise Shaw (Royal United Hospitals Bath NHS Foundation Trust, Bath, UK), Lekhjung Thapa (Upendra Devkota Memorial-National Institute of Neurological and Allied Sciences, Kathmandu, Nepal), Bogdan Wojtyniak (National Institute of Public Health, Warsaw, Poland), Jie Yang (First Affiliated Hospital of Chengdu Medical College, Chengdu, China), and Tomasz Zdrojewski (Medical University of Gdańsk, Gdańsk, Poland) for their comments on early draft of the manuscript. The views expressed in this article are solely the responsibility of the authors and they do not necessarily reflect the views, decisions, or policies of the institution with which they are affiliated. We thank WSO for funding. The funder had no role in the design, data collection, analysis and interpretation of the study results, writing of the report, or the decision to submit the study results for publication. Funding Information: VLF declares that the PreventS web app and Stroke Riskometer app are owned and copyrighted by Auckland University of Technology; has received grants from the Brain Research New Zealand Centre of Research Excellence (16/STH/36), Australian National Health and Medical Research Council (NHMRC; APP1182071), and World Stroke Organization (WSO); is an executive committee member of WSO, honorary medical director of Stroke Central New Zealand, and CEO of New Zealand Stroke Education charitable Trust. AGT declares funding from NHMRC (GNT1042600, GNT1122455, GNT1171966, GNT1143155, and GNT1182017), Stroke Foundation Australia (SG1807), and Heart Foundation Australia (VG102282); and board membership of the Stroke Foundation (Australia). SLG is funded by the National Health Foundation of Australia (Future Leader Fellowship 102061) and NHMRC (GNT1182071, GNT1143155, and GNT1128373). RM is supported by the Implementation Research Network in Stroke Care Quality of the European Cooperation in Science and Technology (project CA18118) and by the IRIS-TEPUS project from the inter-excellence inter-cost programme of the Ministry of Education, Youth and Sports of the Czech Republic (project LTC20051). BN declares receiving fees for data management committee work for SOCRATES and THALES trials for AstraZeneca and fees for data management committee work for NAVIGATE-ESUS trial from Bayer. All other authors declare no competing interests. Publisher Copyright: © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 licenseStroke is the second leading cause of death and the third leading cause of disability worldwide and its burden is increasing rapidly in low-income and middle-income countries, many of which are unable to face the challenges it imposes. In this Health Policy paper on primary stroke prevention, we provide an overview of the current situation regarding primary prevention services, estimate the cost of stroke and stroke prevention, and identify deficiencies in existing guidelines and gaps in primary prevention. We also offer a set of pragmatic solutions for implementation of primary stroke prevention, with an emphasis on the role of governments and population-wide strategies, including task-shifting and sharing and health system re-engineering. Implementation of primary stroke prevention involves patients, health professionals, funders, policy makers, implementation partners, and the entire population along the life course.publishersversionPeer reviewe

The performance of the jet trigger for the ATLAS detector during 2011 data taking

The performance of the jet trigger for the ATLAS detector at the LHC during the 2011 data taking period is described. During 2011 the LHC provided proton–proton collisions with a centre-of-mass energy of 7 TeV and heavy ion collisions with a 2.76 TeV per nucleon–nucleon collision energy. The ATLAS trigger is a three level system designed to reduce the rate of events from the 40 MHz nominal maximum bunch crossing rate to the approximate 400 Hz which can be written to offline storage. The ATLAS jet trigger is the primary means for the online selection of events containing jets. Events are accepted by the trigger if they contain one or more jets above some transverse energy threshold. During 2011 data taking the jet trigger was fully efficient for jets with transverse energy above 25 GeV for triggers seeded randomly at Level 1. For triggers which require a jet to be identified at each of the three trigger levels, full efficiency is reached for offline jets with transverse energy above 60 GeV. Jets reconstructed in the final trigger level and corresponding to offline jets with transverse energy greater than 60 GeV, are reconstructed with a resolution in transverse energy with respect to offline jets, of better than 4 % in the central region and better than 2.5 % in the forward direction